CSL Behring announced that the company’s distribution agreement with Ferring Pharmaceuticals for STIMATE® nasal spray recently expired and will not be renewed effectively removing this medication as a valuable treatment opti
NHF's Wednesday Webinars for May 2021 will focus on Women's Health Month, featuring topics of interest to both patients and healthcare providers who are interested in issues faced by women with inheritable blood disorders.
The von Willebrand disease (VWD) pre-conference brings together the VWD community to connect in a lively, engaging and supportive educational environment. This year, we will focus on the elements of reconnecting, rebuilding and refocusing as a community. We will explore the many ways that we as a community can help raise awareness of VWD and help those who are unaware of their status. We’ll also discuss new medical updates and NHF’s course of action with VWD. Sponsored by CSL Behring.
2020 is the year that VWD guidelines will be announced. This will be an opportunity to learn, explore, and understand the new measures for treatment, diagnosis, and protocols.
This session will review the signs and symptoms of von Willebrand disease, discuss genetics and inheritance patterns, and define and compare the three types of VWD. The presentation will also cover laboratory diagnosis and its challenges, and the therapeutic options available for people with VWD. In addition, you will learn important skills to advocate for yourself and loved ones.
A research abstract presented at the recent Thrombosis & Haemostasis Summit of North America 2020 Virtual Conference suggested that epidural analgesia may be a safe option for pregnant women with von Willebrand disease (VWD) type 1, provided clotting factors are maintained at certain levels.
This activity, “An Introduction to the Recognition, Appropriate Diagnosis, and Timely Management of VWD and other Bleeding Disorders among Women in Non-Hematology Health Care Settings,” is the second module in a three-part series entitled Improving Outcomes for von Willebrand Disease and Other Bleeding Disorders in Non-Hematology Health Care Settings. Each webinar in this series has been designed to better educate healthcare providers who do not specialize in hematology.
This activity, “Advanced Considerations for the Recognition, Appropriate Diagnosis, and Timely Management of VWD and Other Bleeding Disorders among Women in Non-Hematology Health Care Settings,” is the third module in a three-part series entitled Improving Outcomes for von Willebrand Disease and Other Bleeding Disorders in Non-Hematology Health Care Settings. Each webinar in this series has been designed to better educate healthcare providers who do not specialize in the field of hematology.
As the first module in a three-part series entitled Improving Outcomes for von Willebrand Disease and Other Bleeding Disorders in Non-Hematology Health Care Settings, this webinar “Symptom Recognition and Appropriate Early Intervention in Males with von Willebrand Disease” is designed to better educate healthcare providers about the symptoms and clinical management of males with von Willebrand disease.
